Introduction
The Knee injury and Osteoarthritis Outcome Score (KOOS) is one of the most widely used patient reported outcome measures for evaluation of conditions surrounding total knee arthroplasty. However, the KOOS score contains 42 items, which leads to a large burden of completion for the patient and of scoring for the provider. Subsequently, the KOOS 12 was developed as an abbreviated version of the original with the hope that it will have a higher compliance rate, leading to better data capture.
It’s stated purpose is to elicit people’s opinions about the difficulties they experience due to problems with their knee.
The KOOS-12 contains 12 questions, with each question scored from 0 to 4 points, with 0 representing no knee problems and 4 representing extreme knee problems.
The KOOS-12 Summary Knee Impact Score is calculated as an average of the Pain, Function, and Quality of Life scale scores. Overall, scores range from 0 to 100, where, in contrast to the individual questions, 0 is the worst possible and 100 is the best possible score.
YOU CAN USE THIS FORM BELOW TO ASSESS YOUR PATIENT AND PRINT IT OUT OR SAVE AS PDF FILE.
Literature
Original Literature:
- Gandek, B., et al. “Item selection for 12-item short forms of the Knee injury and Osteoarthritis Outcome Score (KOOS-12) and Hip disability and Osteoarthritis Outcome Score (HOOS-12).” Osteoarthritis and Cartilage 27.5 (2019): 746-753.
- Gandek, B., et al. “A 12-item short form of the Knee injury and Osteoarthritis Outcome Score (KOOS-12): tests of reliability, validity and responsiveness.” Osteoarthritis and Cartilage 27.5 (2019): 762-770.
Additional Literature:
Eckhard, Lukas, et al. “The KOOS-12 shortform shows no ceiling effect, good responsiveness and construct validity compared to standard outcome measures after total knee arthroplasty.” Knee Surgery, Sports Traumatology, Arthroscopy (2020): 1-8.
Score developer:
John E. Ware Jr., PhD is a Professor at the University of Massachusetts Medical School, an Adjunct Research Professor at Tufts University School of Medicine and is also the Chief Science Officer and Chairman of the John Ware Research Group.